Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series - Archive ouverte HAL Access content directly
Journal Articles Journal of clinical lipidology Year : 2017

Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series

Abstract

A sudden and severe drug-induced decrease in plasma high-density lipoprotein cholesterol (HDL-C) is a rare condition. We report 2 patients with familial hypercholesterolemia treated with statins and fibrates and 2 others with mixed dyslipidemia treated with fibrates, who presented with a sudden and severe decrease in HDL-C (from -44% to -95%, compared with baseline). Three of the patients were treated with fibrates and had a sudden decrease in HDL-C after the adjunction of ezetimibe. HDL-C returned to normal levels after discontinuation of the offending therapies. In 2 of these patients, the reintroduction of ezetimibe with no fibrates did not affect HDL-C. In conclusion, we report a new profile of patients who are at risk for a sudden drop of HDL-C related to treatment with a combination of fibrates and ezetimibe. Although a sudden drop of HDL-C is a rare event, we recommend to carefully monitor plasma HDL-C in patients submitted to both drugs.
No file

Dates and versions

hal-01601147 , version 1 (02-10-2017)

Identifiers

Cite

Estelle Nobecourt, Bertrand Cariou, Gilles Lambert, Michel Krempf. Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series. Journal of clinical lipidology, 2017, 11 (1), pp.289-293. ⟨10.1016/j.jacl.2016.10.012⟩. ⟨hal-01601147⟩
96 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More